- Stocks
- Healthcare
- NASDAQ: VRTX

Price (delayed)

$207.46

Market cap

$54.04B

P/E Ratio

25.87

Dividend/share

N/A

EPS

$8.02

Enterprise value

$49.73B

The gross profit has soared by 58% YoY and by 13% from the previous quarter

VRTX's revenue has soared by 56% YoY and by 12% QoQ

Vertex Pharmaceuticals's net income has increased by 38% QoQ but it has decreased by 6% YoY

The EPS has increased by 37% since the previous quarter but it has declined by 8% year-on-year

What are the main financial stats of VRTX

Market
Valuations
Earnings

Shares outstanding

260.47M

Market cap

$54.04B

Enterprise value

$49.73B

Price to earnings (P/E)

25.87

Price to book (P/B)

7.15

Price to sales (P/S)

9.97

EV/EBIT

21.75

EV/EBITDA

20.79

EV/Sales

9.2

Revenue

$5.4B

EBIT

$2.29B

EBITDA

$2.39B

Free cash flow

$2.56B

Per share
Balance sheet
Liquidity

EPS

$8.02

Free cash flow per share

$9.85

Book value per share

$29

Revenue per share

$20.81

TBVPS

$33.95

Total assets

$10.22B

Total liabilities

$2.7B

Debt

$522.07M

Equity

$7.52B

Working capital

$4.9B

Debt to equity

0.07

Current ratio

3.72

Quick ratio

3.47

Net debt/EBITDA

-1.8

Margins
Efficiency
Dividend

EBITDA margin

44.3%

Gross margin

87.7%

Net margin

38.5%

Operating margin

38.9%

Return on assets

23.8%

Return on equity

32.9%

Return on invested capital

79.6%

Return on capital employed

27.2%

Return on sales

42.3%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Vertex Pharmaceuticals stock price performed over time

How have Vertex Pharmaceuticals's revenue and profit performed over time

Revenue

$5.4B

Gross profit

$4.74B

Operating income

$2.1B

Net income

$2.08B

Gross margin

87.7%

Net margin

38.5%

The operating income has surged by 139% year-on-year and by 28% since the previous quarter

The gross profit has soared by 58% YoY and by 13% from the previous quarter

VRTX's revenue has soared by 56% YoY and by 12% QoQ

The operating margin has soared by 53% YoY and by 14% QoQ

What is Vertex Pharmaceuticals's growth rate over time

What is Vertex Pharmaceuticals stock price valuation

P/E

25.87

P/B

7.15

P/S

9.97

EV/EBIT

21.75

EV/EBITDA

20.79

EV/Sales

9.2

The EPS has increased by 37% since the previous quarter but it has declined by 8% year-on-year

The price to earnings (P/E) is 29% less than the last 4 quarters average of 36.2

The stock's price to book (P/B) is 56% less than its 5-year quarterly average of 16.1 and 23% less than its last 4 quarters average of 9.3

The equity has grown by 48% YoY and by 16% from the previous quarter

VRTX's revenue has soared by 56% YoY and by 12% QoQ

The price to sales (P/S) is 34% less than the 5-year quarterly average of 15.1 and 24% less than the last 4 quarters average of 13.1

How efficient is Vertex Pharmaceuticals business performance

The return on invested capital has surged by 137% year-on-year and by 32% since the previous quarter

The return on sales has surged by 61% year-on-year and by 14% since the previous quarter

The return on equity has declined by 36% year-on-year but it has grown by 25% since the previous quarter

VRTX's return on assets is down by 34% year-on-year but it is up by 25% since the previous quarter

What is VRTX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for VRTX.

How did Vertex Pharmaceuticals financials performed over time

Vertex Pharmaceuticals's total assets has increased by 45% YoY and by 15% QoQ

The total liabilities has increased by 37% YoY and by 11% QoQ

VRTX's debt is 93% lower than its equity

The equity has grown by 48% YoY and by 16% from the previous quarter

The debt to equity fell by 42% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.